Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2006

View Archived Issues

Novagali completes phase II study of ophthalmic formulation of ciclosporin

Chemicon and MorphoSys sign licensing agreement for research antibodies

Lantibio and TRB Chemedica sign agreement for Vismed

Canadian clearance for phase I study of SL-017 for acne and hair removal

Avid Radiopharmaceuticals closes first institutional financing round

Connetics to acquire PediaMed sales organization

SIRT1 activation: a new target for AD / News in Context

SB-509 set for phase II trial in diabetic neuropathy in H2 2006

New maintenance study of Peg-Intron in HCV patients coinfected with HIV

Hana Biosciences reports 2005 and 2006 milestones

Human Genome Sciences and Amgen sign license agreement

New peripherally selective DBH inhibitor from BIAL

Vitor shows therapeutic effect in cancer cachexia

Lucentis maintained or improved vision in approximately 95% of patients at one year

Benefits of memantine sustained for 1 year in Alzheimer's disease patients

Dosing, pharmacokinetics of BAY-43-9006 investigated in cancer patients

Interleukin-2 improves efficacy of WX-G250 in renal cell carcinoma

4F-Benzoyl-TE-14011 investigated in metastatic bladder cancer

BXL-628 can reduce prostate volume in benign prostatic hyperplasia

Fourth quarter update from Genzyme

New agents described for treating cardiovascular disorders

New possible treatments for gastrointestinal disorders described in recent patents

Recent GSK patent imparts novel agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...